Press Release

Feb, 08 2024

Unveiling the Oncogenic Power: How KRAS Mutations Propel Cancer Initiation and Progression Dynamics

Kirsten rat sarcoma (KRAS) mutations exert a profound impact on cancer initiation and progression by serving as key drivers of uncontrolled cell growth, evasion of apoptosis, and enhanced tumor survival. The altered signaling pathways associated with KRAS mutations disrupt cellular regulatory mechanisms, leading to the development and progression of certain cancers. As a pivotal oncogenic driver, KRAS plays a crucial role in promoting the relentless proliferation of cancer cells and inhibiting programmed cell death. Recognizing the central role of KRAS in these processes highlights its significance as a therapeutic target.

Access Full Report @

Data Bridge Market Research analyses the North America Kirsten Rat Sarcoma (KRAS) Market, which was USD 91.41 million in 2022, is expected to reach up to USD 130 million by 2030 and is expected to undergo a CAGR of 4.50% during the forecast period of 2023 to 2030. The North America kirsten rat sarcoma (KRAS) market is propelled by substantial investments and progress in research and development (R&D) activities, particularly in the pharmaceutical and biotechnology sectors. These initiatives focus on unraveling the molecular intricacies of KRAS mutations and devising precise therapeutic interventions, thereby fostering innovation and driving market growth.

Key Findings of the Study

North America Kristen Rat Sarcoma (KRAS) Market

Increasing strategic collaborations is expected to drive the market's growth rate

Strategic collaborations form a pivotal driver in the North America kirsten rat sarcoma (KRAS) market by fostering synergies among pharmaceutical companies, research institutions, and healthcare organizations. These partnerships enable the efficient pooling of resources, expertise, and valuable data, thereby expediting the development of impactful KRAS-targeted therapies and advanced diagnostic solutions. The collaborative efforts harness collective strengths to navigate the complexities of KRAS-related cancers, ensuring a more coordinated and accelerated approach to innovation. These collaborations play a crucial role in shaping the landscape of KRAS-focused research and contributing significantly to the market's growth trajectory by promoting knowledge exchange and shared capabilities.

Report Scope and Market Segmentation

Report Metric


Forecast Period

2023 to 2030

Base Year


Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product (Reagents and Kits, Analyzers, Consumables), Cancer Type (Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Cervical Cancer, Skin Cancer, Kidney Cancer, Blood Cancer, Ovarian Cancer, Others), Age Group (Adult, Pediatric), Application (Development of Molecular Diagnostics, Disease Diagnostics, Drug Discovery and Development, Personalised Medicine, Predictive, Research and Development, Therapeutic Approach/ Prognostics and Others), End User (Academic and Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Oncology Speciality Clinics, Pharma and Biotech Companies, and Others), Distribution Channel (Direct Tenders, Retail Sales, Third Party Distributor)

Countries Covered

U.S., Canada and Mexico in North America

Market Players Covered

B.D. (U.S.), COSMED srl (Italy), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN (Germany), Agilent Technologies Inc. (U.S.), Merck KGaA (Germany), Carestream Health  (U.S.), Illumina, Inc. (U.S.), Thermo Fisher Scientific (U.S.), AbbVie Inc. (U.S.)

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The North America kirsten rat sarcoma (KRAS) market is segmented on the basis of product, cancer type, age group, application, end user and distribution channel.

  • On the basis of product, the North America kirsten rat sarcoma (KRAS) market is segmented into reagents and kits, analyzers, and consumables
  • On the basis of cancer type, the North America kirsten rat sarcoma (KRAS) market is segmented into lung cancer, colorectal cancer, pancreatic cancer, breast cancer, prostate cancer, cervical cancer, skin cancer, kidney cancer, blood cancer, ovarian cancer, and others
  • On the basis of age group, the North America kirsten rat sarcoma (KRAS) market is segmented into adult, and paediatric
  • On the basis of application, the North America kirsten rat sarcoma (KRAS) market is segmented into development of molecular diagnostics, disease diagnostics, drug discovery and development, personalised medicine, predictive, research and development, therapeutic approach/ prognostics and others
  • On the basis of end user, the North America kirsten rat sarcoma (KRAS) market is segmented into academic and cancer research institutes, diagnostic laboratories, hospitals, oncology speciality clinics, pharma and biotech companies and others
  • On the basis of distribution channel, the North America kirsten rat sarcoma (KRAS) market is segmented into direct tenders, retail sales, third party distributor

Major Players

Data Bridge Market Research recognizes the following companies as the major North America kirsten rat sarcoma (KRAS) market players in North America kirsten rat sarcoma (KRAS) market are B.D. (U.S.), COSMED srl (Italy), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN (Germany), Agilent Technologies Inc. (U.S.), Merck KGaA (Germany), Carestream Health (U.S.)

North America Kristen Rat Sarcoma (KRAS) Market

Market Developments

  • In 2022, Erasca, Inc. announced plans for a clinical trial exploring the combination of a KRAS G12C inhibitor with the ERK1/2 inhibitor ERAS-007. With a focus on non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) driven by the KRAS G12C mutation, this trial reflects a strategic approach to precision oncology. By targeting multiple components of the RAS/MAPK pathway, Erasca aims to evaluate the potential synergistic effects of these inhibitors, potentially expanding the therapeutic options for patients with KRAS-mutant cancers
  • In January 2022, BridgeBio Pharma, Inc. revealed a non-exclusive clinical collaboration with Amgen Inc. The collaboration aims to assess the combination of BBP-398, an SHP2 inhibitor, with LUMAKRAS (sotorasib), a KRASG12C inhibitor. Focusing on patients with advanced solid tumors carrying the KRAS G12C mutation, this partnership highlights the industry's commitment to exploring combination therapies. Such collaborations could pave the way for novel treatment strategies and potentially enhance the efficacy of existing KRAS inhibitors
  • In 2021, Illumina, Inc. strategically forged collaboration with key industry players, namely Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck. This strategic collaboration marked a pivotal step towards the development of standardized precision oncology tools. Illumina aimed to revolutionize genomic profiling, contributing to more effective and tailored cancer treatments by pooling resources and expertise. The synergies formed through these partnerships were expected to elevate the precision of genomic analysis and position Illumina for substantial market growth in the evolving field of precision medicine
  • In 2021, Mirati Therapeutics and the University of Texas MD Anderson Cancer Center, Inc. entered into a strategic collaboration in research and development. The collaboration aims to broaden the assessment of Mirati's investigational KRAS inhibitors, adagrasib (MRTX849) and MRTX1133. The evaluation, both as monotherapy and in combination with other agents, underscores the importance of comprehensive approaches to KRAS-mutant cancers. This collaboration emphasizes the exploration of multiple KRAS mutations, demonstrating a commitment to addressing the heterogeneity within the KRAS market
  • In 2020, Thermo Fisher Scientific Inc. expanded its collaboration with Symphogen, reinforcing its dedication to providing innovative cancer treatments. The focus of this extended collaboration centered on the optimization of protein characterization and quality monitoring mass spectrometry workflows. This collaboration empowered the companies to offer compliance-ready mass spectrometer solutions to the biopharmaceutical industry, thereby playing a crucial role in advancing drug delivery technologies. By combining their expertise, Thermo Fisher Scientific and Symphogen aimed to contribute significantly to the enhancement of cancer treatment methodologies, providing the industry with cutting-edge tools for efficient drug delivery

Regional Analysis

Geographically, the countries covered in the North America kirsten rat sarcoma (KRAS) market report are U.S., Canada and Mexico in North America.

As per Data Bridge Market Research analysis:

U.S. is estimated to be the fastest growing country in North America kirsten rat sarcoma (KRAS) market the forecast period 2023-2030

The U.S. is expected to experience significant market growth, marked by the highest compound annual growth rate (CAGR) in the forecast period, primarily attributed to the increasing incidence of cancer associated with Kristen rat sarcoma (KRAS) mutation. This prevalence has made KRAS a focal point for research and therapeutic development. The nation's substantial investments in Research and Development (R&D) within the healthcare and biopharmaceutical sectors further contribute to its leadership role in advancing cancer research. Additionally, the rapid penetration of novel products in the U.S. market, addressing the challenges posed by KRAS mutations, serves as a key driver for growth.

For more detailed information about the North America kirsten rat sarcoma (KRAS) market report, click here –

Client Testimonials